ImmunityBio (NASDAQ:IBRX) Trading 2.2% Higher – Time to Buy?

ImmunityBio, Inc. (NASDAQ:IBRX) shares traded up 2.2% during trading on Thursday . The company traded as high as $7.35 and last traded at $7.30. 14,023,419 shares were traded during mid-day trading, a decline of 63% from the average session volume of 38,415,582 shares. The stock had previously closed at $7.14.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company raised ~$100M for global expansion, a near‑term liquidity boost that can support operations and development. ImmunityBio (IBRX) Rallies 15% as Firm Raises $100M For Global Expansion
• Positive Sentiment: Company reported its strongest quarter ever per media coverage, which investors may view as operational momentum despite the controversy. IBRX stock notches strongest quarter ever
• Neutral Sentiment: Multiple law firms are issuing investor alerts and invitations to join or lead class actions — procedural notices that increase public attention and could accelerate filings but do not by themselves change the company’s legal exposure. (Examples: Robbins Geller, Kessler Topaz, Faruqi, Pomerantz, Rosen, Levi & Korsinsky.) Robbins Geller investor notice
• Negative Sentiment: FDA issued a warning letter finding some promotional statements about Anktiva misleading; that regulatory finding triggered a major sell‑off (reported ~21% decline and ~$2B market‑cap loss) and is the core allegation in ensuing securities lawsuits. That materially raises regulatory and litigation risk. Hagens Berman on FDA warning and share plunge
• Negative Sentiment: Several securities‑fraud class actions have been filed (and many firms are soliciting lead‑plaintiff applicants) alleging material misstatements/omissions about Anktiva between Jan 19 and Mar 24, 2026; potential damages and legal costs pose downside risk and could distract management. Kessler Topaz class action announcement

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. HC Wainwright raised their target price on ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Piper Sandler reaffirmed an “overweight” rating and issued a $12.00 target price (up from $7.00) on shares of ImmunityBio in a research report on Wednesday, March 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Finally, D. Boral Capital reissued a “buy” rating and set a $23.00 price target on shares of ImmunityBio in a research report on Monday, March 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $14.40.

ImmunityBio Trading Up 2.2%

The stock has a fifty day simple moving average of $7.73 and a 200-day simple moving average of $4.33. The company has a market capitalization of $7.51 billion, a PE ratio of -19.21 and a beta of 0.13.

ImmunityBio (NASDAQ:IBRX) last issued its earnings results on Monday, February 23rd. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. The business had revenue of $38.29 million for the quarter. As a group, equities research analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Insider Buying and Selling

In other news, Director Barry J. Simon sold 165,000 shares of ImmunityBio stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the transaction, the director directly owned 2,925,821 shares of the company’s stock, valued at $29,989,665.25. The trade was a 5.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Christobel Selecky sold 50,000 shares of the stock in a transaction on Friday, January 16th. The stock was sold at an average price of $5.00, for a total transaction of $250,000.00. The SEC filing for this sale provides additional information. Insiders have sold a total of 501,967 shares of company stock worth $4,466,412 in the last 90 days. 69.48% of the stock is currently owned by company insiders.

Institutional Trading of ImmunityBio

Institutional investors have recently modified their holdings of the business. Walser Wealth Management Company A Ltd Liability Co acquired a new stake in shares of ImmunityBio in the fourth quarter valued at approximately $59,000. Invesco Ltd. boosted its holdings in ImmunityBio by 14.6% in the fourth quarter. Invesco Ltd. now owns 182,836 shares of the company’s stock valued at $362,000 after acquiring an additional 23,353 shares during the last quarter. Corient Private Wealth LLC grew its position in ImmunityBio by 69.7% during the fourth quarter. Corient Private Wealth LLC now owns 333,149 shares of the company’s stock valued at $660,000 after acquiring an additional 136,858 shares during the period. EP Wealth Advisors LLC acquired a new stake in ImmunityBio during the fourth quarter worth about $35,000. Finally, Empowered Funds LLC acquired a new stake in ImmunityBio during the fourth quarter worth about $28,000. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.